JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥386.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥74.37B
Enterprise Value¥110.28B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)638.6
Beta0.93
Next Earnings
May 07, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)0.27
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.27
Price to Sales (P/S)1.81
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥710.00Price Target Upside-0.28% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)16.19
Revenue Forecast (FY)¥38.71B
Bulls Say, Bears Say
Bulls Say
Niche Biopharma FocusJCR's strategic focus on rare diseases and advanced biologics creates durable competitive advantages: higher clinical and regulatory barriers to entry, specialist physician networks, and often favorable reimbursement dynamics. This niche supports pricing power, longer product life cycles and partnership appeal over months to years.
Recent Revenue GrowthReported revenue growth of ~7.17% suggests underlying demand and execution in commercial channels despite other pressures. Sustained mid-single-digit growth can support incremental margin recovery, justify continued investment in specialty pipelines and manufacturing capacity, and underpins medium-term revenue resilience.
Healthy Equity BaseA healthy equity ratio and stable equity base provide a structural buffer against operational shocks and financing needs. This balance-sheet strength supports access to capital for clinical programs or manufacturing scale-up and reduces short-term insolvency risk while management addresses other financial issues.
Bears Say
Negative Cash GenerationNegative operating and free cash flows indicate the company is not generating sufficient cash from core operations and is reliant on external funding. Over a 2–6 month horizon this constrains R&D, commercialization and manufacturing investments and raises refinancing or dilution risk if not corrected.
Rising Debt LevelsAn increasing debt load and higher debt-to-equity reduce financial flexibility and increase interest obligations. For a specialty pharma with episodic revenues, higher leverage elevates default risk, limits ability to pursue partnerships or capex, and pressures free cash flow during adverse cycles.
Negative ProfitabilitySustained negative net, EBIT and EBITDA margins show the business is currently unprofitable. Persistent losses erode retained earnings, weaken ROE, and force strategic choices on pricing, portfolio prioritization or cost structure. That undermines long-term reinvestment capacity and shareholder returns.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥74.37B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on Jan 28, 2026. The company reported ¥0.27 earnings per share for the quarter, beating the consensus estimate of -¥1.072 by ¥1.342.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -1.14.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥0.27 in its last earnings report, beating expectations of -¥1.072. Following the earnings report the stock price went down -2.519%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥710.00
▼(-0.28% Downside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---